Atlas Trials

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Clinical trial NCT05191472 · TERMINATED

Trial details

NCT number
NCT05191472
Sponsor
Alfred Chung, MD
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, RefractoryRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Start date
2022-05-03
Primary completion
2023-12-31
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.